Rutgers Innovation’s Post

Neuspera Medical Inc. closed its Series D funding round, raising $23 million 💰. The funding was led by Vertex Ventures HC and Treo Ventures, with participation from Action Potential Venture Capital, Windham Venture Partners, Olympus Innovation Ventures, and other strategic investors. Neuspera is making an Implantable Sacral Neuromodulation (SNM) System. This discreet, ultra-miniaturized implant is designed to provide personal control and relief from urinary urge incontinence (UUI), a common symptom of overactive bladder (OAB) affecting millions of adults. OAB can significantly impact daily life, leading to issues like depression and social stigma. The Neuspera System stands out as the least invasive sacral neuromodulation device. Its innovative design includes a pulse generator and electrode array that fit snugly within the sacral foramen, eliminating the need for invasive procedures. Patients can enjoy the benefits without noticeable scars or discomfort, regaining control of their symptoms and enhancing their quality of life. This funding will support Neuspera Medical through the anticipated U.S. FDA premarket approval (PMA) of the Neuspera System. This is a step forward in providing less invasive, adaptable treatment options for chronic illnesses. CEO of Neuspera Steffen Hovard said: “We’re excited to bring new partners on board as we approach the next significant milestone of submitting the Neuspera System for regulatory approval,” “The confidence and conviction of our new and existing investors, like Olympus Innovation Ventures, demonstrates the strength and potential of our platform technology.” #neuromodulation #neurotech #funding

We are happy to announce that Angel Investors of STAN invested in Denovo Sciences for the second time, marking our 23rd deal. Denovo Sciences is a deep technology company that creates novel therapeutics using state-of-the-art AI technologies. The startup applies Deep Reinforcement Learning (DRL) to address complex challenges in drug discovery. Denovo Sciences was developed as part of the Foundation for Armenian Science and Technology (FAST) Advanced Solutions Center (ASCENT) program. It was a venture builder program where researchers and scientists collaborated on in-depth idea exploration, followed by comprehensive feasibility studies, proof of concept, and later prototype development. Following the ASCENT program, Denovo Sciences has successfully raised pre-seed and seed funding, gaining the trust of investors from Armenia and abroad, including support from Berkeley SkyDeck, Granatus Ventures, Triple S Ventures, SASTIC, EU institutions, and others. The startup has published 8 peer-reviewed articles, contributing innovative findings in the field of drug discovery. In addition to its scientific contributions, Denovo has formed partnerships with leading companies in the biotech sector from the US, UK, Singapore, and Switzerland, accelerating research and drug development. We are excited to continue the support making the second investment and be part of their journey since the early days. Congratulations to Denovo Sciences and STAN Angel Investors on this partnership! #STAN #DenovoSciences #investmentnews #Armeniansartupecosystem #deeptech

Congrats to Vivalyx, an innovative Organ Vitality Tech startup based in Aachen, on successfully closing an oversubscribed seed funding round, raising above EUR 5 million. Investors include leading European Life Science and Deeptech venture capital firms such as Brightlands Venture Partners, TechVision Fonds, Arve Capital, the American Deeptech VC Goose Capital, and notable private angel investors.   The funding enables Vivalyx to finance the clinical study required for regulatory approval. This crucial step paves the way for the launch of the innovative organ preservation solution, which has the potential to extend the lifespan of donor organs and enhance their vitality. Vivalyx technology aims to significantly increase the number of organs available for transplantation, thus saving and improving the lives of patients worldwide – at significantly lower costs, considerably reduced complexity, and streamlined processes.   Thumbs up also to the international Orrick team including Ilona Schütz, David Hamala, Sven Greulich, Benedikt Migdal and further colleagues.   Orrick, Herrington & Sutcliffe LLP #medtech #lifesciences #organdonation #venturecapital #founders #innovation #TeamOrrick

We're thrilled to announce that Legal-Pythia has been named one of the top 50 startups to watch in the Glasgow City Region! 🚀 This recognition is a powerful validation of our mission to revolutionize legal operations through AI. We're honored to be included among the most promising companies in the region. Let's continue to push the boundaries of legal tech together! #LegalTech #Startup #Glasgow #Innovation #AI #LegalPythia #FinTech #ExplainableAI #Financials #FinancialServices #FraudDetection #documentautomation #ukstartup #legalindustry

Advice from those who've been there and done it is always helpful. Starting or scaling a business in Life Science or Tech? Have a look/listen.

🚨 MintNeuro funding round announcement 🚨 Parkwalk recently invested in MintNeuro, an Imperial College London spinout and innovative startup at the dynamic intersection of neurotechnology and semiconductors. This capital raise will enable MintNeuro to accelerate delivery of its silicon roadmap and advance clinical deployment of next-generation implantable devices, designed to treat major neurological disorders including epilepsy, Parkinson's and dementia. Martin Glen, Investment Director at Parkwalk, said: “MintNeuro’s innovative technology has the potential to change the lives of millions of patients suffering from a diverse range of neurological conditions. Its accessible, adaptable solution represents a major advancement in treatment options, and we’re extremely excited to be supporting the team in its journey to revolutionise neurological care.” Read the full press release here: https://lnkd.in/eiC7qeJM Parkwalk invested alongside Empirical Ventures, Imperial College London, Plug and Play Tech Center, Excellis and several prominent angel investors. #InvestinginInnovation #spinout #EIS #medtech #neurotechnology

Swedish startup’s $26 million Series A funding marks a turning point in cellular communication mapping Moleculent, a Stockholm-based company focused on advancing the spatial mapping of cell-cell communication, has secured a significant milestone with the closing of its oversubscribed $26 million Series A financing round. This round was co-led by ARCH Venture Partners and Eir Ventures, with participation from existing investors. The funding will support Moleculent’s innovative functional biology platform, which enables the detection and profiling of cell-cell interactions directly within tissue environments. Moleculent announced key appointments to its leadership team. Patrick A. Weiss from ARCH Venture Partners has been appointed Chairman of the Board, while Sean Kendall from ARCH and Magnus Persson from Eir Ventures have joined the company’s Board of Directors. https://lnkd.in/d6v87T7R #nordicmade #sweden #funding #deeptech #lifesciences #biotech #healthtech #startups #trending

🚀 We're super excited to share that Q Bio has closed a $27 million strategic funding round, and we are thrilled to be part of this journey. This investment is set to turbocharge their mission of making preventive healthcare accessible and affordable for everyone. Joining the amazing existing investors at a16z Bio + Health, Founders Fund and Khosla Ventures we are proud to lead this round. Why We’re Backing Q Bio: 🔍 All-In-One Health Check: Q Bio combines whole-body MRI scans with urine and blood tests, biomarkers, and your genetic & medical history to create a super detailed #digitaltwin profile. This helps catch health issues early and keep you on top of your game. 🏥 Three Game-Changing Tech Pillars: - Gemini Software: Integrates with any 3rd party MRI machines to give you clear exam summaries and risk assessments. - Mark I Full Body Scanner: This scanner can do a full-body check in just 10 minutes without the usual claustrophobia or radiation worries. Significant leap from the traditional MRI tech. - Anatomical Foundation Model (AFM): Uses AI to detect any anomalies, helping radiologists focus only on what needs a closer look. Tackling the Big Challenges: 💡 Cutting Costs, Boosting Efficiency: Q Bio's tech makes preventive health scans cheaper and faster. The Mark I scanner is low maintenance and high throughput, cutting down on costs and making multiple scans feasible, reducing false positives. Looking Ahead: This funding is all about making advanced health scans more accessible. We're thrilled to partner with Q Bio and help drive better health outcomes on a large scale. Terry Doyle TELUS Global Ventures (TGV) Mike Titkov #HealthcareInnovation #PreventiveHealth #DigitalTwin #MRI #AI #SeriesAFunding #QBio #PersonalizedHealth #HealthcareRevolution Read more about this exciting development in STAT's latest article linked in the post below.

Rob Weisman from the Boston Globe reports, "Last year, nearly 60 percent of venture capital for Massachusetts life sciences companies was deployed to companies outside Cambridge, the highest share since 2019, when the Massachusetts Biotechnology Council began tracking that metric, according to a report the council released this month. That increased from 51 percent outside Cambridge in 2022 to 42 percent in 2021. The new clusters are already having a broad impact on communities outside the traditional biotech hub, bringing jobs, tax revenue, and a cutting-edge vibe but also more traffic and pressure on real estate costs. Venture dollars stayed largely within Eastern Massachusetts last year, but moves are afoot to accelerate the industry’s expansion to cities and towns in the state where space is more plentiful. “We need the scale, in terms of space, that isn’t ideally suited for Cambridge,” said David Hallal, chief executive of ElevateBio, which outfitted a 300,000-square-foot facility to make cell and gene therapies near the intersection of Routes 2 and 128 in Waltham. Six-year-old Elevate, which has about 300 employees in Massachusetts, reeled in the state’s largest venture capital round in 2023. It raised just over $400 million to expand capacity at its “genetic medicines foundry,” a contract manufacturing plant that supports more than 20 drug makers. Other large venture outlays went to biotech startups such as Cardurion Pharma in Burlington ($300 million), Aiolos Bio in Boston’s Back Bay ($245 million), MapLight Therapeutics in Burlington ($225 million), Upstream Bio in Waltham ($200 million), and Abcuro in Newton ($155 million). Mariana Oncology ($174 million) is one of several early-stage drug developers that leased space at 100 Forge, a nine-story glass tower that opened in 2022 behind the Arsenal Yards development in Watertown." See the link below for the full article. #biotechnology #biotech #biotechnologie #lifesciences #science #research #biotechnews https://lnkd.in/exPy7mYv

🔥 Thrilled to share that Simpact Ventures has led a €3M seed round for Ligence, a #Lithuanian medtech startup transforming cardiac diagnostics! Joining us were Coinvest Capital, EIC Fund, Lemonade Stand, NGL Ventures, and Rita Sakus. #Ligence’s AI-powered echocardiography software streamlines image analysis, supporting cardiologists 💊 with precise, guideline-aligned measurements. Unlike typical “black box” tech, their platform integrates smoothly with hospital systems for clearer, actionable insights. With this funding, Ligence aims to make cardiac ultrasound more accessible and accurate, supporting earlier diagnoses, enhanced risk assessments, and better patient screening. This breakthrough also alleviates the manual workload for cardiologists, giving them more time to focus on patient care. ❤️🩹 Kudos to everyone involved! 👏 Read more: https://lnkd.in/dcfphtiS #impactinvesting #medtech #healthcareinnovation #cardiology #investment #digitalhealth